{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"8.5","value":"3.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"DoR is defined as the time from first documented CR or PR until disease progression or death from any cause, based on local investigator's assessment according to RECIST criteria v1.1.","dispersionType":"Full Range","groups":[{"description":"Patients will receive INCMGA00012 500 mg by intravenous infusion on Day1 of each cycle.\n\nRetifanlimab: INCMGA00012 500 mg will be administered on Day1 of each cycle (once every four weeks), for up to 2 years.","id":"OG000","title":"Interventional Arm"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From baseline until disease progression or treatment discontinuation, up to 10.3 months","title":"Efficacy Determined by Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"months"}